Watch out, Merck: FDA grants Regeneron, Sanofi's Libtayo priority review for coveted first-line use in lung cancer

One month after Regeneron and Sanofi posted impressive data from a phase 3 trial of their PD-1 inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), the FDA has shifted the drug into the fast lane—possibly offering the companies a chance to challenge the undisputed leader in that market, Merck’s Keytruda.